Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

PT 523

Known as: PT-523, PT523 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

talotrexin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier
The reduced folate carrier (RFC) and the proton-coupled folate transporter (PCFT) are ubiquitously expressed in normal and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2004
Highly Cited
2004
Characterization of a Folate Transporter in HeLa Cells with a Low pH Optimum and High Affinity for Pemetrexed Distinct from the Reduced Folate Carrier
Studies were undertaken to characterize a low pH transport activity in a reduced folate carrier (RFC)-null HeLa-derived cell line… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2004
Highly Cited
2004
Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
A methotrexate (MTX)-resistant HeLa subline (R5), developed in this laboratory, with impaired transport due to a genomic deletion… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2002
Highly Cited
2002
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
We determined the mechanisms of resistance of human CCRF-CEM leukemia cells to methotrexate (MTX) vs. those to six novel… Expand
2002
2002
A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
Pemetrexed is a novel antifolate effective in the treatment of mesothelioma. Studies were undertaken to characterize the… Expand
  • figure 2
  • figure 1
  • figure 4
  • figure 3
Highly Cited
2000
Highly Cited
2000
Folate depletion increases sensitivity of solid tumor cell lines to 5‐fluorouracil and antifolates
Cancer cell lines in standard cell culture medium or in animal models are surrounded by an environment with relatively high… Expand
1999
1999
Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514)
Since the early 1950s, extensive research efforts have been devoted to the discovery and development of antifolate… Expand
1997
1997
NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase.
The antitumor compound PT523 [N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine] was found to have an… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
1997
Highly Cited
1997
Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523…
Structural data for two independent crystal forms (monoclinic, C2, and orthorhombic, P2(1)2(1)2(1)) of the ternary complex of the… Expand
1994
1994
Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Studies on the mode of action of PT523 [N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine], a potent… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE